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REVIEW ARTICLE
Native T1 Reference Values for
Nonischemic Cardiomyopathies and
Populations With Increased Cardiovascular
Risk: A Systematic Review and
Meta-analysis
Maaike van den Boomen, MS,1* Riemer H.J.A. Slart, MD, PhD,2
Enzo V. Hulleman, MD,3 Rudi A.J.O. Dierckx, MD, PhD,4
Birgitta K. Velthuis, MD, PhD,5 Pim van der Harst, MD, PhD,6
David E. Sosnovik, MD,7 Ronald J.H. Borra, MD, PhD,8 and
Niek H.J. Prakken, MD, PhD3
Background: Although cardiac MR and T1 mapping are increasingly used to diagnose diffuse fibrosis based cardiac dis-
eases, studies reporting T1 values in healthy and diseased myocardium, particular in nonischemic cardiomyopathies
(NICM) and populations with increased cardiovascular risk, seem contradictory.
Purpose: To determine the range of native myocardial T1 value ranges in patients with NICM and populations with
increased cardiovascular risk.
Study Type: Systemic review and meta-analysis.
Population: Patients with NICM, including hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), and
patients with myocarditis (MC), iron overload, amyloidosis, Fabry disease, and populations with hypertension (HT), dia-
betes mellitus (DM), and obesity.
Field Strength/Sequence: (Shortened) modified Look–Locker inversion-recovery MR sequence at 1.5 or 3T.
Assessment: PubMed and Embase were searched following the PRISMA guidelines.
Statistical Tests: The summary of standard mean difference (SMD) between the diseased and a healthy control popula-
tions was generated using a random-effects model in combination with meta-regression analysis.
Results: The SMD for HCM, DCM, and MC patients were significantly increased (1.41, 1.48, and 1.96, respectively, P <
0.01) compared with healthy controls. The SMD for HT patients with and without left-ventricle hypertrophy (LVH)
together was significantly increased (0.19, P5 0.04), while for HT patients without LVH the SMD was zero (0.03,
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P5 0.52). The number of studies on amyloidosis, iron overload, Fabry disease, and HT patients with LVH did not meet
the requirement to perform a meta-analysis. However, most studies reported a significantly increased T1 for amyloidosis
and HT patients with LVH and a significant decreased T1 for iron overload and Fabry disease patients.
Data Conclusions: Native T1 mapping by using an (Sh)MOLLI sequence can potentially assess myocardial changes in
HCM, DCM, MC, iron overload, amyloidosis, and Fabry disease compared to controls. In addition, it can help to diag-
nose left-ventricular remodeling in HT patients.
Level of Evidence: 2
Technical Efficacy: Stage 3
J. MAGN. RESON. IMAGING 2017;00:000–000.
Nonischemic cardiomyopathy (NICM) is a prevalentdisease characterized by different patterns of fibrosis in
the myocardium that can eventually cause heart failure.
According to the American Heart Association (AHA) and
the National Institutes of Health (NIH), NICM comprises
a heterogeneous group of cardiac diseases presenting as:
hypertrophic cardiomyopathy (HCM), dilated cardiomyopa-
thy (DCM), or restrictive cardiomyopathy (RCM).1 HCM
alone affects 1/500 adults2 and its prevalence increases with
age. Other populations also have an increased risk of devel-
oping NICM according to the AHA. These include the
one-third of the USA population that has high blood pres-
sure,3 the approximately one-tenth that suffers from diabe-
tes4; and the two-thirds that are either overweight (body
mass index [BMI] 25) or obese (BMI 30).5,6
Early detection of NICM is of key importance in pre-
venting major cardiac events. However, the subtle changes
that are often seen in the early stages of NICM are difficult
to detect and distinguish from normal variation. Cardiac
MR is commonly used to diagnose NICM by imaging stan-
dard parameters such as ventricular function, wall-mass, and
myocardial fibrosis using late gadolinium enhancement
(LGE).7–9 In the more advanced stages of NICM, cardiac
MR can reveal fibrosis combined with either an increase in
wall-mass (HCM) or in dilatation of the ventricular cavity
(DCM).10 However, in the earlier stages of NICM the
increases in wall-mass and dilation are less obvious, and the
fibrosis patterns remain difficult to detect. This makes it dif-
ficult to recognize NICM at the onset of the disease.11 It is
even more difficult to distinguish NICM from hypertension
(HT), diabetes melitus type 2 (DM), or obesity, because of
their similarities in cardiac characteristics,12 especially when
left-ventricle hypertrophy (LVH) is present. Common char-
acteristics include: increased left ventricular wall-thickness,13
diastolic dysfunction,14 increased left ventricle mass,15 and
infiltration of myocardial fat.15 These similarities may lead
to incorrect interpretation and possible mistreatment. There-
fore, additional diagnostic techniques are needed to ensure
accurate diagnosis of NICM.
T1 mapping has been proposed as a technique to aid
earlier diagnosis of NICM patients.11 Previous research has
shown that cardiac native T1-mapping can differentiate
between healthy myocardial tissue and pathologies including
HCM, myocarditis (MC), iron loading, amyloidosis, and
Fabry disease.16 In addition, T1 values of myocardial tissue
in HT patients without LVH do not seem to change,13,17
suggesting that it may be possible to differentiate HT from
NICM tissue. Further research is needed to determine
whether T1 mapping can enable earlier detection of these
NICM.
Although there are concerns about the physical accu-
racy of T1 mapping, the overall precision and reproducibil-
ity are fairly high and of substantial clinical utility.18 There
is, therefore, an increasing demand for normative reference
T1 values.
19–21 These reference values will be of particular
importance for HT, DM, and obese patients because they
share cardiac MR characteristics with NICM.13–15 Because
methodological differences can eventually affect the myocar-
dial T1 values,
18,21 a meta-analysis is a suitable approach to
determine the normal myocardial T1 reference values.
Materials and Methods
Search Strategy
In June 2017, two independent reviewers (M.v.d.B and E.V.H) sys-
tematically searched for eligible studies published since 2011 in
PubMed/MEDLINE and EMBASE using cardiac T1 mapping in
humans. The search was restricted to studies to NICM, cardiac
inflammatory, or storage diseases and populations with increased
cardiovascular risk. Keywords used were “cardiomyopathy,”
“hypertension,” “obesity,” “diabetes mellitus,” “magnetic resonance
imaging,” and “T1-mapping” (see online Appendix for full search
term).
Studies were included if they 1) published results from ran-
domized controlled trials or cohort studies; 2) investigated human
adults; 3) included subjects with NICM, MC, iron overload, amy-
loidosis, HT, DM or obesity who underwent cardiac MR with T1
mapping; 4) contained native T1 values from a modified Look–
Locker inversion-recovery (MOLLI)22–24 or shortened MOLLI
(ShMOLLI)25 sequence; and 5) excluded subjects with a history of
coronary artery disease or myocardial infarction. Studies had to be
available in full text, published in peer-reviewed journals, and writ-
ten in English. No additional hand-searched papers were found.
The Preferred Reporting Items for Systemic Reviews and Meta-
Analysis (PRISMA) statement26 and the Cochrane Handbook for
Systematic Review27 were used to perform and report this system-
atic review and meta-analysis.
Study Selection
M.v.d.B and E.V.H. independently assessed the title and abstract of
the studies that were proposed by the databases. Full-text reports
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of the eligible studies were obtained and again independently
assessed by these same authors for inclusion in this review. Differ-
ences of opinion between the two authors were resolved, which led
to consensus about included papers. Quality assessment was per-
formed by using the Newcastle-Ottawa quality assessment scale
(NOS), in which the quality of the study was appraised using three
domains: selection of study groups (0–4 stars), comparability of
groups (0–2 stars), and ascertainment of exposure/outcome (0–3
stars). The cohort or case control version of the NOS was used,
depending on the study type.
Data Collection
Data were extracted by the same authors noting: study population,
age, gender, BMI, native T1 value, magnetic field strength (Tesla),
vendor, imaging analysis method, and MR sequence. No authors
were contacted for additional information. The data were collected
as reported (mean6 standard deviation). The mean and standard
deviation were calculated using the approach of Hozo et al.28 for
studies that only reported the median with interquartile (IQR) or
full range. For studies with multiple groups, only the data from
the relevant population were extracted. The data of healthy control
groups (controls) were also extracted.
Data Analysis
The T1 outcome values of the individual studies were combined in
a random-effects model, leading to computations of standard mean
difference (SMD) and 95% confidence intervals (CI). I2 was used
as a measure of heterogeneity with I2  50% and P < 0.05 on the
v2 test defined as a significant degree of heterogeneity. This was
further explored by meta-regression, bias, and sensitivity analyses
for groups with sufficient (>10) included studies.27 A mixed-effect
model approach was used for the meta-regression and performed
with available covariates to determine association with the myocar-
dial T1 value. A backwards elimination approach with a removal
criteria of P > 0.05 was used for this. Included covariates were at
least: gender, age, field strength, MRI vendor information, and the
used sequence, even though it is shown that for T1 values under
1200 msec the MOLLI and (Sh)MOLLI have good overall agree-
ment.25 Funnel plots with missing studies analysis and Egger test
were performed to determine publication bias. Sensitivity analysis
was conducted by omitting each study sequentially and recalculat-
ing the model. These statistical analyses were performed using
Review Manager (RevMan) v. 5.3 (Cochrane Collaboration,
Copenhagen, Denmark) and the package “metafor” in R v. 3.22
(R Foundation for Statistical Computing, Vienna, Austria). Fur-
thermore, the weighted mean and weighted standard deviation
were determined separately for all studied populations and field
strengths using the number of subjects as weight-factor. These
results are also presented to give a complete overview of the
analysis.
Results
Results of the Literature Search
The search strategy identified 660 relevant abstracts in
PubMed and EMBASE. In addition, eight handpicked papers
were included. After removing the duplicates, a total of 557
abstracts were evaluated. In total, 49 articles remained for the
meta-analysis; 305 studies were excluded based on title and
abstract, 173 were excluded based on full text screening, and
30 were excluded based on the published data. More specific
reasons for exclusion are listed in Fig. 1. A total of ten studies
were included for the HCM group,17,29–37 nine for
DCM,11,30,33,35,38–42 twelve in MC,30,43–53 five in iron over-
load,54–58 six in amyloidosis,32,59–63 two in Fabry disease,64,65
ten in HT,13,17,34,37,66–71 four in DM,72–75 and one in obe-
sity74 (Table 1). The field strength is known to influence the
T1 values significantly
65; therefore, results from studies per-
formed on a 1.5T or 3T are shown separately, but used as
covariant in the meta-regression analysis.
Study Quality
One study34 received the maximum score in the NOS in all
areas and only two studies46,57 received the full score in the
category of study group selection. Not every study included
a control group, which led to a minimum score at the com-
parability area and a lower score in ascertainment for these
studies. The studies that did include control subjects, but
had a poor description of patient and control subject selec-
tion, received a lower score in the selection category. A total
of 24 studies reported the use of blinded analysis and evalu-
ation by at least two analysts, which increased their score on
ascertainment (see Table 1 for NOS scores).
Hypertrophic and Dilated Cardiomyopathy
The weighted mean (Sh)MOLLI T1 values in HCM
patients and controls, respectively, measured at 1.5T were
FIGURE 1: Overview of study review process according to the
PRISMA flow diagram.26
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10026 52 msec and 9626 37 msec (Table 1, Fig. 2). At
3T these weighted means were 11666 55 msec and
10816 45 msec, respectively (Table 1, Fig. 3). The meta-
analysis showed a significant increase of the myocardial T1
values for HCM patients (SMD5 1.41, 95% CI 0.93–1.88,
P < 0.01, I25 78%, Fig. 4). The meta-regression deter-
mined the machine vendor and the age of HCM patients as
significant covariates, which accounted for the heterogeneity
in the meta-regression model, with no other remaining sig-
nificant residual factors (I25 0%). This indicates that the
FIGURE 2: Weighted mean T1 values with weighted mean and standard deviation of all included studies per HCM, DCM, MC, iron
overload, amyloidosis, HT with (LVH1) and without (LVH–) left ventricular hypertrophy, DM, and OB population (black) and
healthy controls (gray) in 1.5T studies.
FIGURE 3: Weighted mean T1 values with weighted mean and standard deviation of all included studies per HCM, DCM, MC, iron
overload, amyloidosis, HT with (LVH1) and without (LVH–) left ventricular hypertrophy, DM, and obesity population (black) and
healthy controls (gray) in 3T studies.
Journal of Magnetic Resonance Imaging
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SMD between HCM patients and controls is independent
of field strength and MOLLI sequence. Only younger
HCM patients and the use of a Siemens MRI (Avanto or
Trio) scanner were shown to decrease the SMD. No signifi-
cant funnel asymmetry was found for the random or mixed
effect models (P < 0.24 and P < 0.37, respectively). The
sensitivity analysis demonstrated that one study35 influenced
the model, but this was not significant (P > 0.09). This
specific study used a different scanner and a relatively young
HCM patient population (446 11 years) compared to the
other studies.
The weighted mean (Sh)MOLLI T1 values in DCM
patients and controls, respectively, measured at 1.5T were
10086 48 msec and 9706 130 msec (Table 1, Fig. 2). At
3T these were 11656 64 msec and 10806 46 msec, respec-
tively (Table 1, Fig. 3). The meta-analysis confirmed this
increase in T1 values in the myocardium for DCM patients
(SMD5 1.48, 95% CI 0.86–2.10, P < 0.01, I25 85%,
Fig. 5). The heterogeneity and study bias could not be
investigated further, because there were fewer than 10 stud-
ies included that compared DCM patients with controls.
However, an exploratory meta-regression analysis indicated
that the percentage men in the DCM population and the
age of the subjects in the control population might be the
source of heterogeneity.
Myocarditis, Iron Loading, Amyloidosis, and Fabry
Disease
The weighted mean (Sh)MOLLI T1 value in active/acute
MC patients and controls, respectively, measured at 1.5T
were 10546 61 msec and 9496 28 msec (Table 1, Fig. 2).
At 3T these were 11936 60 msec and 10686 36 msec,
respectively (Table 1, Fig. 3). Studies that compared the
active/acute MC patients with controls showed a significant
increase of the T1 value for MC patients. The meta-analysis
confirmed this significant increase (SMD5 1.96; 95% CI
1.42–2.51; I25 91%, P < 0.01, Fig. 6). Significant covari-
ates were vendor and left ventricular ejection fraction
(LVEF) of the MC patients, which accounted for the het-
erogeneity in the meta-regression model with no other
remaining significant residual factors (I25 0%, P5 0.77). A
significant funnel asymmetry was found for the random
effect model with one possible missing study (P5 0.03),
but not for the mixed effect model including the two mod-
erators (P5 0.45). The sensitivity analysis demonstrated
that one study46 introduced some heterogeneity into the
model, but only the 1.5T data of this study had significant
influence on the model fit (P < 0.05).
The weighted mean (Sh)MOLLI T1 value, in iron
overload patients and controls, respectively, measured at
1.5T were 8146 128 msec and 9806 34 msec (Table 1,
Fig. 2). At 3T these were 10106 144 msec and 11626 42
msec, respectively (Table 1, Fig. 3). Only three studies
restricted the inclusion to one specific iron overload patient
population,54–56 the other two studies used a mixed popula-
tion of patients.57,58 The number of included studies was
not sufficient to conduct a meta-analysis, but the direction
of the overall effect was similar for all studies (Fig. 7).
Amyloidosis is the most typical type of restrictive car-
diomyopathy.76 The weighted mean (Sh)MOLLI T1 values
were only measured at 1.5T and were 11406 69 ms for
patients and 9606 29 for controls (Table 1, Fig. 2). Three
FIGURE 4: Standardized mean difference between native myocardial T1 of HCM patients and healthy controls with associated ran-
dom effects weight factors, CI5 confidence interval, IV5 inverse variance.
FIGURE 5: Standardized mean difference between native myocardial T1 of DCM patients and healthy controls with associated ran-
dom effects weight factors, CI5 confidence interval, IV5 inverse variance.
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studies32,60,63 compared amyloidosis patients with controls,
and all concluded that there was a significant increase of the
T1 for amyloidosis patients. Some studies divided the amy-
loidosis patient populations in immunoglobulin light chain
(AL) or transthyretin (ATTR),29 or cardiac or no cardiac
involvement amyloidosis.62,63 Karamitsos et al.63 showed
that all their subpopulations, including no cardiac involve-
ment amyloidosis patients, had a significantly increased T1
value compared to healthy controls. No meta-analysis was
performed because of the small number of included studies.
However, the direction of the overall effect was similar for
all studies (Fig. 8).
Fabry disease is a less common restrictive cardiomyop-
athy and only two studies were included. Nevertheless, the
weighted mean (Sh)MOLLI T1 values at 1.5T were
8756 48 msec for patients and both studies used the same
pool of controls that had T1 values of 9686 23 msec (Table
1, Fig. 2). No further meta-analysis or regression could be
performed on these data (Fig. 9)
Chronic Hypertension, Overweight/Obesity, and
Type 2 Diabetes Mellitus
The weighted mean (Sh)MOLLI T1 value measured by
1.5T was 10446 41 for HT patients with LVH, 9846 41
msec for HT patients without LVH, and 9756 40 msec for
controls (Table 1, Fig. 2). At 3T these were 10706 68
msec for HT patients and 10236 41 msec for controls
(Table 1, Fig. 3). Four studies13,17,68,69 compared HT
patients with LVH to controls and HT patients without
LVH. They all reported a significant increase of T1 of the
LVH populations compared with controls (P < 0.05) and
three13,68,69 also reported a significant increase compared
with HT patients without LVH, while this last group had
no significant change in T1 values. Two studies
34,37 com-
pared HT patients to HCM patients. The comparison with
HT without LVH showed a significant higher T1 value for
HCM patients (P < 0.01),34 while the comparison with
HT with LVH showed no significant difference between the
two.37 The meta-analysis of all HT patients (with and
FIGURE 7: Standardized mean difference between native myocardial T1 of iron overload (IO) patients and healthy controls with
associated random effects weight factors, CI5 confidence interval, IV5 inverse variance.
FIGURE 8: Standardized mean difference between native myocardial T1 of amyloidosis (AM) patients and healthy controls with
associated random effects weight factors, CI5 confidence interval, IV5 inverse variance.
FIGURE 6: Standardized mean difference between native myocardial T1 of MC patients and healthy controls with associated ran-
dom effects weight factors, CI5 confidence interval, IV5 inverse variance.
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without LVH) together showed a significant difference
between T1 values of healthy controls and HT patients
(SMD: 0.19; 95% CI 0.01–0.37; I25 61%; P5 0.04, Fig.
10). The meta-regression analysis showed that in HT
patients LVH was the only significant covariate which
changed the I2 to 4%. A second meta-regression was per-
formed excluding those patients with LVH. The analysis of
the HT patients without LVH showed no significant differ-
ence between the T1 values of healthy controls and HT
patients (SMD: 0.03; 95% CI –0.07–0.13; I25 2%;
P5 0.52, Fig. 11). Analysis on funnel symmetry, missing
studies or influencing studies, of this restricted inclusion all
turned out to be not significant for both analyses (HT with-
out LVH: P < 0.83, P5 0.5, and P > 0.05, respectively,
and all HT: P5 0.09, P5 0.5, P > 0.05, respectively).
DM and obese patient populations are studied less
extensively with T1-mapping compared with the above-
mentioned diseases. The weighted mean MOLLI T1 value
measured on 1.5T was 8536 202 msec for DM
patients,72–74 9636 116 msec for obesity subjects and
9866 87 msec for controls74 (Table 1, Fig. 2). At 3T the
only measured T1 values were 11946 32 msec for DM
patients and 11826 28 msec for controls75 (Table 1, Fig.
3). No meta-analysis was performed, because of the small
number of included studies (Figs. 12 and 13).
Discussion
The findings of this systematic review and meta-analysis
show that native myocardial T1 values changes significantly
in patients with HCM, DCM, MC, amyloidosis, and iron
overload. This supports previously published research on the
diagnostic value of native T1 mapping to detect diffuse
myocardial fibrosis, inflammation, iron accumulation, and
protein deposition.16,77 HT patients without any LVH
FIGURE 10: Standardized mean difference between native myocardial T1 of all HT patients and healthy controls with associated
random effects weight factors, CI5 confidence interval, IV5 inverse variance, F15 female subgroup, M15male subgroup.
FIGURE 9: Standardized mean difference between native myocardial T1 of Fabry (FA) disease patients and healthy controls with
associated random effects weight factors, CI5 confidence interval, IV5 inverse variance.
FIGURE 11: Standardized mean difference between native myocardial T1 of HT patients without LVH with associated random
effects weight factors, CI5 confidence interval, IV5 inverse variance, F15 female subgroup, M15male subgroup.
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showed no significant change in the T1 value, which indi-
cates the absence of the tissue modifications, while HT
patients with LVH had a significantly increased T1 value.
Insufficient numbers of publications have been conducted in
Fabry disease and populations with increased cardiovascular
risk (DM and obesity) to draw any conclusions about
changes in those myocardial T1 values.
The current meta-analysis confirms the clinical poten-
tial of T1 mapping,
78,79 but also shows a lack of standardi-
zation considering the different reported T1 values for
controls. Although T1 values at 1.5T seemed to vary, none
of the T1 values of the controls were significantly different
from the expected MOLLI T1 value of 9506 21 msec.
80 In
studies performed at 3T, none of the T1 values for controls
were significantly different from the expected MOLLI T1
value of 10536 23 msec.80 Moon et al.21 stressed the need
to improve standardization of T1 mapping by describing
protocol recommendations. However, they also state that
there is no current standard for T1 mapping sequences, nor
for analysis and mapping methods. It is recognized that the
T1 value is influenced by these factors, which probably led
to the inconsistencies in the reported T1 values.
18
In addition, the postprocessing of the T1 map can also
introduce bias, errors, and loss of precision, particularly in
protocols using regional regions of interest (ROIs), image
segmentation, variable slice orientations.21 Almost half of
the included studies used ROIs to determine the
T1.
32,35,38–42,45,49,51,53–55,57–62,66,68–71 Conversely, Moon
et al.21 recommended global myocardial T1 measurements.
Puntmann et al. clearly showed the importance of this in
their studies on DCM patients.11,35,42 They used rectangu-
lar ROIs in the septum, the average of the whole short axis
slice (SAX). The T1 value for the whole SAX showed no
significant difference between DCM patients and controls
(P5 0.05), while the T1 values in the septal ROI were sig-
nificantly increased for DCM patients (P < 0.05).
In addition to this, the T1 values of studies that used the
segmental approach also suffered from averag-
ing.31,38,47,48,52,59,61,67,70,72,73 Furthermore, some studies
used the 4-chamber plane for T1 mapping,
29,32,60–63 which
can lead to errors due to through-plane respiratory motion.
All these factors, together with the lack of standard proto-
cols, make it difficult to determine a normative T1 value
range for healthy myocardium, and therefore also for dis-
eased myocardium.
Fortunately, SMD between controls and the studied
cardiac diseases are shown to be less variable across studies
and sites. The SMDs were shown to be independent of the
applied field strength and MR sequence, and only for the
HCM and MC population the SMD did depend on the
system type (vendor). Moon et al.21 recommend correcting
for variation in the scanner’s characteristics and this meta-
analysis demonstrates that this correction should probably
mainly be based on vendor. Apart from the variation and
lack of standardization, the SMD shows that native T1 has
diagnostic value for most of the included cardiac diseases.
NICM can have subtle and diffuse fibrosis patterns
that are difficult to determine11 and inclusion and study
bias are a remaining concern in NICM studies. The funnel
plots and Egger tests show that there is indeed some publi-
cation bias for the MC analysis, which should be kept in
mind when evaluating the SMD. However, none of the
other populations showed this bias, and only showed hetero-
geneity in T1 values caused by the vendor, age or gender.
These factors are well known to influence myocardial T1
values and are important to correct for.21,81 In addition,
some studies32,33,36,41 reported T1 values of LGE-based
ROIs, which is known to be highly nonspecific and misses
the full representation of the disease.21,82 These LGE-based
ROI data were excluded from the meta-analysis. After cor-
recting the SMD for these heterogeneity factors, the meta-
analysis still shows that there are significant changes in T1,
FIGURE 13: Standardized mean difference between native myocardial T1 of obese (OB) populations and healthy controls with
associated random effects weight factors, CI5 confidence interval, IV5 inverse variance.
FIGURE 12: Standardized mean difference between native myocardial T1 of DM patients and healthy controls with associated
random effects weight factors, CI5 confidence interval, IV5 inverse variance.
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and although LGE is still the clinical standard to determine
focal fibrosis, a change of native T1 is clearly also associated
with an increase in fibrotic tissue.16
In addition to sensitivity for myocardial fibrosis, T1
values can also indicate edema formation (inflammation),
and deposition of substances like protein and iron, which
makes it a nonspecific parameter.16,78 T1 values seem sensi-
tive enough to differentiate between clinical disease stages of
patients with myocarditis when a baseline scan and clinical
records are provided.46,49,83 T1 values may therefore help to
follow disease progression and treatment83; however, this
meta-analysis only confirms the significant changes in myo-
cardial T1 values in the acute phase of MC.
Iron accumulation also changes myocardial T1 values by
shortening the relaxation times significantly, which suggests
T1 mapping is also of value in the assessment of myocardial
iron loading.55,64 One of the included studies57 evaluated the
T2 of an iron overload patient population and concluded
that one-third had a normal T2 but a decreased T1 value.
They state that T1 mapping might be more sensitive to iron
accumulation than T2 imaging, but the amount of accumu-
lated iron that correlates with these T1 values still needs to be
confirmed by human histology. The differences in iron con-
centration of all included subjects in the different studies
might have caused the broad range in T1 values. Further
research to the correlation between T1 values and the iron
concentration in the myocardium is needed to determine
whether T1 mapping could also be used for monitoring.
All amyloidosis studies reported a significant increase in
myocardial T1 values, even for amyloidosis patients who had
no biopsy or decreased cardiac function that confirmed car-
diac involvement. This meta-analysis shows that it is sensitive
to increases of the interstitial space caused by myocardial pro-
tein depositions in amyloidosis,16 which indicates that myo-
cardial T1 mapping might be better in early detection of
amyloidosis deposition in the heart than regular cardiac MRI.
The significant increase SMD is even found when there is a
high variation caused by the studies that used the 4-chamber
imaging plane for T1 mapping, which is commonly used to
study amyloidosis patients.29,32,60 Further research with car-
diac axial slices is needed to determine the classification
potential of the T1 value in amyloidosis patients.
HT and NICM patients seem to have several standard
cardiac MR parameters in common; nevertheless, none of
the included studies in this meta-analysis reported a signifi-
cant increase in T1 values for HT patients without LVH.
Only patients with HT in combination with LVH showed a
significant change in T1 value.
68,69 However, all studies
reported the mean T1 value, which ignores the fact that HT
might be associated with inhomogeneous T1 distribution.
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Further research is needed to determine the ability of T1
mapping to image this inhomogeneity and whether it is
applicable to follow HT progression.
Two studies reported clearly decreased T1 values for
DM,72,73 but had no healthy control population to compare
them with. A reason for this decrease might be that DM
patients are known to develop myocardial steatosis due to
their insulin resistance, and the associated myocardial fat
lowers the native T1 value.
74 However, the fat content of
this myocardial steatosis is much smaller than in Fabry dis-
ease, and the number and size of T1 mapping studies was
too small to determine the influencing factors in this popu-
lation. Two other studies reported much higher T1 for DM
patients and compared them with healthy controls, but both
showed no significant change.74,75 Levelt et al75 used
healthy control subjects with a BMI of 28.66 5.7, which
raises the question whether healthy controls should have a
healthy weight (BMI <25). This concern is the same for
the DM populations, because the DM patients in the
included studies had a weighted mean BMI of 316 5,
which makes most of them obese. Only one study85 com-
pared DM patients with a lean group of healthy controls
and obese controls separately. However, the obesity subjects
did not differ significantly from either of the two other pop-
ulations in this study. Further research with lean controls
and DM patients (BMI <25) is needed to confirm the
reported changes in T1 value, and whether it is possible to
distinguish these populations from NICM patients.
T1 mapping has numerous MRI-dependent and meth-
odological factors that can influence the final T1 values.
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The field strength and sequence are two of these factors, but
this meta-analysis shows that they do not influence the
SMD, even though the T1 values at 3T are overall 100msec
higher than at 1.5T. More research towards understanding
the effect on accuracy, precision, and reproducibility of T1
mapping is needed.21,86 Without this knowledge, it remains
unknown whether the variance of the T1 maps is mainly
caused by variability in physiological effects, or the inaccu-
racy of the technique itself. The HCM, DCM, MC, and
HT patient populations were studied in groups of sufficient
size to suggest that the significant SMD of T1 values is
probably caused by changes in tissue physiology. Further
research should be conducted on DM and obese popula-
tions and on other possible factors associated with variance
in T1 mapping values.
The nonuniform reporting of data in the included
studies: heterogeneity of included patient populations, meth-
ods for T1 mapping, differences in ROI placement, and for
amyloidosis, iron overload, DM, and obese, and the small
number of studies formed the major limitations of this
meta-analysis. Most studies did not publish their data per
patient, especially the studies with great sample sizes, and
therefore no conclusions could be drawn on a per-patient
basis. Future prospective studies should provide complete
patient-level insight, which may help mitigate selection bias
for amyloidosis, iron overload, DM, and obese studies. In
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addition, the patient characteristics should be published
together with the T1 values to enable determination of cor-
relation. Finally, we had to compare the T1 values of a
smaller number of amyloidosis, iron overload, DM, and
obese studies with more widely studied HCM, DCM, MC,
and HT diseases. However, the direction of the overall effect
was similar for the iron overload and amyloidosis studies
and can be ascribed to the physiological changes associated
with the diseases. For the DM and obese populations, this
direction is less obvious.
In conclusion, this meta-analysis shows that native T1
mapping is a reliable way to distinguish HCM, DCM, MC,
iron overload, amyloidosis, and HT patients with LVH
from healthy controls and HT patients without LVH. This
indicates that T1 mapping could help diagnose certain car-
diomyopathies at an earlier stage than other cardiac MR
techniques alone. In addition, DM and OB seem to affect
myocardial T1 values, although the change in T1 is opposite
to that seen in noninfiltrative NICM. Further research into
these risk populations is needed to determine the degree of
overlap in myocardial T1 values in the healthy, cardiovascu-
lar risk, and NICM populations.
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